Cargando…

Regulator combinations identify systemic sclerosis patients with more severe disease

Systemic sclerosis (SSc) is a heterogeneous autoimmune disorder that results in skin fibrosis, autoantibody production, and internal organ dysfunction. We previously identified 4 “intrinsic” subsets of SSc based upon skin gene expression that are found across organ systems. Gene expression regulator...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yue, Franks, Jennifer M., Yang, Monica, Toledo, Diana M., Wood, Tammara A., Hinchcliff, Monique, Whitfield, Michael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526449/
https://www.ncbi.nlm.nih.gov/pubmed/32721949
http://dx.doi.org/10.1172/jci.insight.137567
_version_ 1783588877009682432
author Wang, Yue
Franks, Jennifer M.
Yang, Monica
Toledo, Diana M.
Wood, Tammara A.
Hinchcliff, Monique
Whitfield, Michael L.
author_facet Wang, Yue
Franks, Jennifer M.
Yang, Monica
Toledo, Diana M.
Wood, Tammara A.
Hinchcliff, Monique
Whitfield, Michael L.
author_sort Wang, Yue
collection PubMed
description Systemic sclerosis (SSc) is a heterogeneous autoimmune disorder that results in skin fibrosis, autoantibody production, and internal organ dysfunction. We previously identified 4 “intrinsic” subsets of SSc based upon skin gene expression that are found across organ systems. Gene expression regulators that underlie the SSc-intrinsic subsets, or are associated with clinical covariates, have not been systematically characterized. Here, we present a computational framework to calculate the activity scores of gene expression regulators and identify their associations with SSc clinical outcomes. We found that regulator activity scores can reproduce the intrinsic molecular subsets, with distinct sets of regulators identified for inflammatory, fibroproliferative, limited, and normal-like samples. Regulators most highly correlated with modified Rodnan skin score (MRSS) also varied by intrinsic subset. We identified subgroups of patients with fibroproliferative and inflammatory SSc with more severe pathophenotypes, such as higher MRSS and increased likelihood of interstitial lung disease (ILD). Using an independent cohort, we show that the group with more severe ILD was more likely to show forced vital capacity decline over a period of 36–54 months. Our results demonstrate an association among the activation of regulators, gene expression subsets, and clinical variables that can identify patients with SSc with more severe disease.
format Online
Article
Text
id pubmed-7526449
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-75264492020-10-05 Regulator combinations identify systemic sclerosis patients with more severe disease Wang, Yue Franks, Jennifer M. Yang, Monica Toledo, Diana M. Wood, Tammara A. Hinchcliff, Monique Whitfield, Michael L. JCI Insight Research Article Systemic sclerosis (SSc) is a heterogeneous autoimmune disorder that results in skin fibrosis, autoantibody production, and internal organ dysfunction. We previously identified 4 “intrinsic” subsets of SSc based upon skin gene expression that are found across organ systems. Gene expression regulators that underlie the SSc-intrinsic subsets, or are associated with clinical covariates, have not been systematically characterized. Here, we present a computational framework to calculate the activity scores of gene expression regulators and identify their associations with SSc clinical outcomes. We found that regulator activity scores can reproduce the intrinsic molecular subsets, with distinct sets of regulators identified for inflammatory, fibroproliferative, limited, and normal-like samples. Regulators most highly correlated with modified Rodnan skin score (MRSS) also varied by intrinsic subset. We identified subgroups of patients with fibroproliferative and inflammatory SSc with more severe pathophenotypes, such as higher MRSS and increased likelihood of interstitial lung disease (ILD). Using an independent cohort, we show that the group with more severe ILD was more likely to show forced vital capacity decline over a period of 36–54 months. Our results demonstrate an association among the activation of regulators, gene expression subsets, and clinical variables that can identify patients with SSc with more severe disease. American Society for Clinical Investigation 2020-09-03 /pmc/articles/PMC7526449/ /pubmed/32721949 http://dx.doi.org/10.1172/jci.insight.137567 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Wang, Yue
Franks, Jennifer M.
Yang, Monica
Toledo, Diana M.
Wood, Tammara A.
Hinchcliff, Monique
Whitfield, Michael L.
Regulator combinations identify systemic sclerosis patients with more severe disease
title Regulator combinations identify systemic sclerosis patients with more severe disease
title_full Regulator combinations identify systemic sclerosis patients with more severe disease
title_fullStr Regulator combinations identify systemic sclerosis patients with more severe disease
title_full_unstemmed Regulator combinations identify systemic sclerosis patients with more severe disease
title_short Regulator combinations identify systemic sclerosis patients with more severe disease
title_sort regulator combinations identify systemic sclerosis patients with more severe disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526449/
https://www.ncbi.nlm.nih.gov/pubmed/32721949
http://dx.doi.org/10.1172/jci.insight.137567
work_keys_str_mv AT wangyue regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease
AT franksjenniferm regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease
AT yangmonica regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease
AT toledodianam regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease
AT woodtammaraa regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease
AT hinchcliffmonique regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease
AT whitfieldmichaell regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease